ABX464-108
41 evidence topics · 6 sources
Objective
Purpose stated in the ClinicalTrials.gov record
Objective of the three-year interim analysis
Location and study date
Study dates and status in the ClinicalTrials.gov record
“Active, not recruiting” (opens the source at this quote in a new tab)
“Study Start (Actual) 2021-12-03” (opens the source at this quote in a new tab)
“Primary Completion (Estimated) 2028-03” (opens the source at this quote in a new tab)
“Study Completion (Estimated) 2028-04” (opens the source at this quote in a new tab)
Registered locations
Data cutoff of the three-year interim analysis
Study design
Design details in the ClinicalTrials.gov record
| Field | Quoted record |
|---|---|
| Allocation | “N/A” |
| Interventional model | “Single Group Assignment” |
| Interventional model description | “Open Label Follow-up Study” |
| Masking | “None (Open Label)” |
| Phase | “Phase 2” |
| Enrollment (estimated) | “203” |
Treatment period and follow-up in the ClinicalTrials.gov record
Dose de-escalation after the phase 2a and phase 2b open-label maintenance studies
Design described in the congress poster
Phase 2 program schema
“Obefazimod 50 mg (n=22)” (opens the source at this quote in a new tab)
“48 months ~4 years of treatment” (opens the source at this quote in a new tab)
“Obefazimod 50 mg (n=217)” (opens the source at this quote in a new tab)
“48 + 48 weeks ~2 years of treatment” (opens the source at this quote in a new tab)
“Up to 78 months” (opens the source at this quote in a new tab)
Eligibility criteria
Inclusion and exclusion criteria in the ClinicalTrials.gov record
Eligibility criteria shown in the congress presentation
Treatment
Intervention in the ClinicalTrials.gov record
Study outcomes
Rationale for using adverse events as the primary endpoint
Registered primary and secondary outcome measures
Statistical analysis description
Number of participants (Planned and analyzed)
Participants evaluated at the September 2024 data cutoff
Description of analysis sets
Intent-to-treat analysis with non-responder imputation
Non-responder imputation and as-observed analyses
Week 144 completer population and definition of prior advanced therapy inadequate response
Results
Participant disposition
Discontinuations and visit completion through week 144
Baseline characteristics
Clinical remission at study baseline
Characteristics at the start of the 25 mg dose among week 144 completers
| Characteristic | Week 144 completers (n=104) |
|---|---|
| Age, years, mean (SD) | “45.4 (12.74)” |
| Male, n (%) | “65 (62.5)” |
| UC duration, years, mean (SD) | “11.2 (7.02)” |
| Modified Mayo score 0 to 4, n (%) | “104 (100)” |
| C-reactive protein, mg/L, median | “2.2” |
| Fecal calprotectin, µg/g, median | “57.0” |
| Concomitant corticosteroids, n (%) | “6 (5.8)” |
| Concomitant 5-ASA, n (%) | “79 (76.0)” |
| Prior refractoriness to biologics, n (%) | “49 (47.1)” |
| Primary non-response, n (%) | “19 (38.8)” |
| Loss of response, n (%) | “30 (61.2)” |
Efficacy results
Clinical remission at weeks 48, 96, and 144 with non-responder imputation
Clinical and symptomatic remission in the non-responder imputation and as-observed analyses
Efficacy endpoints among week 144 completers by prior advanced therapy inadequate response
| Endpoint and subgroup | Baseline | Week 48 | Week 96 | Week 144 |
|---|---|---|---|---|
| Clinical remission, AT-IR naive (N=57) | “97%” | “91%” | “88%” | “90%” |
| Clinical remission, prior AT-IR (N=47) | “85%” | “77%” | “80%” | “79%” |
| Symptomatic remission, AT-IR naive (N=57) | “97%” | “97%” | “91%” | “95%” |
| Symptomatic remission, prior AT-IR (N=47) | “87%” | “83%” | “85%” | “85%” |
| Endoscopic improvement, AT-IR naive (N=57) | “100%” | “93%” | “95%” | “95%” |
| Endoscopic improvement, prior AT-IR (N=47) | “98%” | “92%” | “91%” | “89%” |
| Endoscopic remission, AT-IR naive (N=57) | “84%” | “77%” | “84%” | “81%” |
| Endoscopic remission, prior AT-IR (N=47) | “45%” | “53%” | “57%” | “62%” |
Fecal calprotectin through week 144
Two-year interim analysis among participants evaluated, September 2024 data cutoff
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Treatment-emergent adverse events in all 130 participants
| Event | N (%) [IR/100 PY] |
|---|---|
| Any TEAE | “96 (73.8) [87.9]” |
| TEAE leading to discontinuation | “9 (6.9) [4.25]” |
| Serious TEAE | “8 (6.2) [3.86]” |
| Ulcerative colitis | “15 (11.5) [7.3]” |
| Nasopharyngitis | “11 (8.5) [5.4]” |
| Upper respiratory tract infection | “10 (7.7) [4.9]” |
| COVID-19 | “11 (8.5) [5.4]” |
| Hypertension | “7 (5.4) [3.4]” |
| Diarrhea | “5 (3.8) [2.4]” |
| Arthralgia | “5 (3.8) [2.4]” |
| Gastroenteritis | “4 (3.1) [1.9]” |
| Non-melanoma skin cancer | “1 (0.8) [0.5]” |
Deaths, opportunistic infections, and laboratory findings
Infections and malignancies across up to 7 years of treatment
Safety at the September 2024 data cutoff
Study limitations
Summary
ABX464-108 (Study 108) is an ongoing single-group, open-label extension without a control group, in which participants who completed the phase 2a (ABX464-102) or phase 2b (ABX464-104) open-label maintenance studies on obefazimod 50 mg, and who had a Mayo endoscopic subscore of 0 or 1 and a rectal bleeding subscore of 0, received obefazimod 25 mg once daily. Entry selected participants already in endoscopic improvement after 2 to 4 years of treatment: of 174 who completed the earlier studies, 138 were eligible and 130 were treated, and 89% (116/130) were in clinical remission at study baseline. The study has no randomized comparison of 25 mg with continued 50 mg. Results come from an interim analysis presented at a congress and in a press release (January 5, 2026 cutoff; February 13, 2026 data transfer); no peer-reviewed report or registry results exist, and primary completion is estimated for March 2028. Clinical remission by non-responder imputation was 73%, 69%, and 68% at weeks 48, 96, and 144. The baseline characteristics and the subgroup analyses by prior advanced therapy inadequate response were reported only for the 104 participants who completed week 144, among whom clinical remission was 84% to 85% in the as-observed analysis. Sources state the treatment period differently: a maximum of 54 months in the registry summary, 78 months in the registry outcome time frame and the poster, and up to five additional years in the press release. The number completing week 48 is 113 in the poster and 114 on a presentation slide, and the number completing the phase 2a extension is 10 in the poster and 11 in the posted ABX464-102 results. The safety table excludes laboratory findings. No health-related quality of life results were located.